Biolase entered the deal with an unnamed institutional investor, according to a June 28 news release.
Under the terms of the agreement, Biolase will sell 1,405,405 shares of common stock or pre-funded warrants in a registered direct offering. The company will also issue warrants to purchase common stock in a private placement.
The deal is expected to close on or about June 30.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place November 12–14 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
